The FDA added a warning to the label of esketamine nasal spray (Spravato), noting that long-term cognitive and memory ...

Approved in March 2019, esketamine is currently indicated for use alongside an oral antidepressant for treatment-resistant ...

Esketamine for TRD demonstrated efficacy in reducing depressive symptoms and did not significantly differ based on TMS treatment history.

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Esketamine nasal spray (Spravato) monotherapy was helpful in improving symptoms of treatment-resistant depression ...

Learn more about how an anesthetic traditionally used for surgical procedures may help depression and what to expect during ...

The FDA has approved Janssen’s antidepressant nasal spray Spravato ... through multiple treatments without relief. Spravato (esketamine) has been touted as a potential blockbuster for Janssen ...

When Dr. Husseini Manji was developing the first-in-class depression medication Spravato at Johnson & Johnson he encountered plenty of naysayers.

I specialize in using an array of treatment modalities, including medication management, psychoeducation, and interventional psychiatric approaches such as esketamine nasal treatment and TMS Therapy.

Objective To investigate the efficacy of esketamine as an adjuvant to epidural ropivacaine for labour analgesia by determining its effect on the median effective concentration (EC 50) in a 20 ml ...